Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| CareDx, Inc.CDNA · Entity 4344 | Director | July 16, 2026 | July 17, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,259 |
Ending reported balance
After 2026-06-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 11,455 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-06-22 · Exercise / conversion · Acquired 2,808 · Balance 14,263 Row 3 · 2026-06-22 · Sale · Disposed 2,808 · Balance 11,455 F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. Row 4 · 2026-06-23 · Sale · Disposed 2,196 · Balance 9,259 F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2035-06-19 | Direct | 5,617 |
Reported balance
After 2026-06-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-22 · Exercise / conversion · Disposed 2,808 · Balance 5,617 F5: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 398 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 398 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
F4: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F5: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
CareDx, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,686 |
Ending reported balance
After 2026-07-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-07-16 · Exercise / conversion · Acquired 7,606 · Balance 44,292 Row 2 · 2026-07-16 · Exercise / conversion · Acquired 16,048 · Balance 60,340 Row 3 · 2026-07-16 · Exercise / conversion · Acquired 5,125 · Balance 65,465 Row 4 · 2026-07-16 · Sale · Disposed 28,679 · Balance 36,786 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-07-16 · Sale · Disposed 100 · Balance 36,686 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-16 · Exercise / conversion · Disposed 7,606 · Balance 0 F3: The option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-16 · Exercise / conversion · Disposed 16,048 · Balance 0 F3: The option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2033-06-15 | Direct | 24,011 |
Reported balance
After 2026-07-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-16 · Exercise / conversion · Disposed 5,125 · Balance 24,011 F3: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $36.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The option is fully vested.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2024 Filed Feb 20, 2024 21:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,915 | $8.45 | $24,631.75 |
DisclosureSEC source: 0000950170-24-017081 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 2,915 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000950170-24-005380 · ownership.xml · derivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,176 Underlying: Common Stock · 2,915 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/3rd of the shares underlying the option vested on June 22, 2023; thereafter, 1/3rd of the underlying shares vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,915 | $37.97 | $110,682.55 |
DisclosureSEC source: 0000950170-24-005380 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,915 | $8.45 | $24,631.75 |
DisclosureSEC source: 0000950170-24-005380 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 2,915 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-23-059101 · doc4.xml · derivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,091 Underlying: Common Stock · 2,915 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. F2 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,915 | $36.12 | $105,289.80 |
DisclosureSEC source: 0001209191-23-059101 · doc4.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,915 | $8.45 | $24,631.75 |
DisclosureSEC source: 0001209191-23-059101 · doc4.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (right to buy) · Derivative | 2,915 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-23-055717 · doc4.xml · derivative · entry 3 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,006 Underlying: Common Stock · 2,915 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. F2 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,915 | $30.00 | $87,450.00 |
DisclosureSEC source: 0001209191-23-055717 · doc4.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,764 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 2,915 | $8.45 | $24,631.75 |
DisclosureSEC source: 0001209191-23-055717 · doc4.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:25 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 51,501 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001209191-23-039396 · doc4.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:52 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 29,136 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001217234-23-000131 · wf-form4_168738794512801.xml · derivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,136 Underlying: Common Stock · 29,136 shares Expires 2033-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2023 and the shares subject to the option shall vest monthly thereafter through June 16, 2024. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:52 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 18,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000131 · wf-form4_168738794512801.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,891 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2024. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:56 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 25,775 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001299130-23-000082 · wf-form4_168513453246545.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,775 Underlying: Common Stock · 25,775 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:26 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 676 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000008 · wf-form4_167330319267954.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,047 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:40 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 422 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000174 · wf-form4_166491963378065.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,371 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:36 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 325 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000139 · wf-form4_165713979220037.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,949 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039270 · doc4.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:09 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 7,606 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001217234-22-000123 · wf-form4_165584574785603.xml · derivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606 Underlying: Common Stock · 7,606 shares Expires 2032-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2022 and the shares subject to the option shall vest monthly thereafter through June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 21:09 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000123 · wf-form4_165584574785603.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,624 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2023. Read SEC document |
| May 25, 2022 Filed May 27, 2022 23:35 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 63,015 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001299130-22-000087 · certent-form4.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,015 Underlying: Common Stock · 63,015 shares Expires 2032-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| December 29, 2021 Filed Jan 4, 2022 00:53 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,764 | $14.23 | $25,101.72 |
DisclosureSEC source: 0000899243-22-000180 · doc4.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,764 Read SEC document |
| December 29, 2021 Filed Jun 30, 2025 21:49 UTC Amendment | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,752 | $14.24 | $24,948.48 |
DisclosureSEC source: 0000950170-25-091759 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,294 Read SEC document |
| December 28, 2021 Filed Feb 13, 2024 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,542 | $12.68 | $19,552.56 |
DisclosureSEC source: 0000950170-24-014537 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,433 Read SEC document |
| December 28, 2021 Filed Feb 13, 2024 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,891 | $13.18 | $24,923.38 |
DisclosureSEC source: 0000950170-24-014537 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,891 Read SEC document |
| December 28, 2021 Filed Feb 13, 2024 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,542 | $12.68 | $19,552.56 |
DisclosureSEC source: 0000950170-24-014523 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 3,433 Read SEC document |
| December 28, 2021 Filed Feb 13, 2024 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,891 | $13.18 | $24,923.38 |
DisclosureSEC source: 0000950170-24-014523 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,891 Read SEC document |
| December 28, 2021 Filed Jun 30, 2025 21:46 UTC Amendment | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 796 | $13.16 | $10,475.36 |
DisclosureSEC source: 0000950170-25-091756 · ownership.xml · nonDerivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 2,687 Read SEC document |
| December 28, 2021 Filed Jun 30, 2025 21:46 UTC Amendment | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 1,542 | $12.68 | $19,552.56 |
DisclosureSEC source: 0000950170-25-091756 · ownership.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,542 Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 50,968 | $0.00 Strike: $48.45 | $0.00 |
DisclosureSEC source: 0000899243-21-041672 · doc4.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,968 Underlying: Common Stock · 50,968 shares Expires 2031-10-24 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after October 25, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 131 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000221 · wf-form4_163338019526676.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,761 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:28 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantEmployee Stock Option (right to buy) · Derivative | 1,630 | $0.00 Strike: $91.99 | $0.00 |
DisclosureSEC source: 0001217234-21-000160 · wf-form4_162526846819039.xml · derivative · entry 2 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 Underlying: Common Stock · 1,630 shares Expires 2031-07-01 F2 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on August 1, 2021 and 1/36th of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:28 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-21-000160 · wf-form4_162526846819039.xml · nonDerivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 F1 · shares: The reported securities are represented by restricted stock units 1/3rd of which shall vest on July 1, 2022 and 1/3rd of which shall vest on each anniversary thereafter. Read SEC document |
| June 16, 2021 Filed Jun 22, 2021 01:46 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 28,992 | $0.00 Strike: $27.90 | $0.00 |
DisclosureSEC source: 0001299130-21-000186 · certent-form4.xml · derivative · entry 1 Valantine Hannah · CIK 0001855608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,992 Underlying: Common Stock · 28,992 shares Expires 2031-06-16 F1 · derivative.exercise_date: Dr. Valantine was elected to the Board of Directors on June 16, 2021. One-third of the shares subject to the option will vest on the one year anniversary of Dr. Valantine joining the Board, and the remainder will vest in equal monthly installments thereafter for 24 months on the same date of the month as her initial start date, provided she continues to serve as a director through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.